Please rotate your device to portrait mode

Board of Directors

Hugues Bultot


Hugues has over 15 years of experience as a CEO and is a serial entrepreneur in the life sciences and biotechnology industries. Prior to MaSThercell, Hugues was CEO and co-founder of Artelis, where he created strong value and assets, later selling the company to ATMI LS in a multi-million dollar deal. Hugues was also CEO of Kitozyme, the world's leading manufacturer of vegetable chitosan, where he successfully implemented the GMP-compliant production facility. Through education and experience, Hugues has developed strong specialities in bio-ventures, fundraising and financial management.

Hugues hold the position of CEO at MaSTherCell until July 2017, to then move to the position of Administrator in MaSThercell's Board of Directors. Besides he is currently the CEO of Univercells, a biomanufacturing engineering company that aims to make biologics available and affordable for all by reinventing the way they are manufactured across the globe. In addition, Hugues is director for Orgenesis, a development stage cell therapy company on a mission to end diabetes, and director for Vivaldi BioSciences, which develops more effective flu vaccines. 

Vered Caplan

Director of Orgenesis

Since 2008, Ms. Caplan has been CEO of Kamedis, a company focused on utilising plant extracts for dermatology purposes. From 2004 to 2007, Ms. Caplan was CEO of GammaCan, a company focused on the use of immunoglobulins for the treatment of cancer. During the previous five years, Ms. Caplan has been a director of the following companies: Opticul Ltd., a company involved with optic based bacteria classification; Inmotion Ltd., a company involved with self-propelled disposable colonoscopies; Nehora Photonics Ltd., a company involved with non-invasive blood monitoring; Ocure Ltd., a company involved with wound management; Eve Medical Ltd., a company involved with hormone therapy for menopause and PMS; and Biotech Investment Corp., a company involved with prostate cancer diagnostics. Ms. Caplan has a M.Sc. in biomedical engineering from Tel-Aviv University specialised in signal processing; management for engineers from Tel-Aviv University specialised in business development; and a B.Sc. in mechanical engineering from the Technion Institute of Technology specialised in software and CAD systems. 

Shimon Hassin

BiondVax Pharmaceuticals Ltd. Chief Operating Officer

Dr. Shimon Hassin, Ph.D., serves as Chief Operating Officer at BiondVax Pharmaceuticals Ltd. Dr. Hassin has over 10 years of experience in Biotechnology, with specific expertise in the development of biopharmaceuticals. Prior to joining the company, Dr. Hassin was co-founder and Chief Executive Officer of Kadimastem. Before joining BiondVax, Dr. Hassin worked at InSight Biopharmaceuticals, a leading Israeli biotechnology company active in the area of Biogenerics. In his capacity as Head of Process Development, he was responsible for the manufacturing of a variety of Biogenerics such as therapeutic antibodies, cytokines and hormones. Dr. Hassin holds a Ph.D. degree in Biotechnology from the University of Maryland Biotechnology Institute and was a post-doctoral associate at the University of Bergen Center of Marine Biotechnology.

Ohad Karnieli (PhD, MBA)

ATVIO Chief Executive Officer & Co-Founder

Dr. Karnieli earned his PhD in Biotechnology focusing on Cell & Gene Therapy from the Sacler school of Medicine at Tel Aviv University and an MBA from the Haifa University school of management. Dr. Karnieli served in several executive rolls in the field of cell therapy and medical devices with his last position being the VP of Technology & Manufacturing at Pluristem Therapeutics. A well-known expert in the field of cell therapy process development and serves on several industry committees including chairing of the process & product development committee of the International Society for Cell Therapy and an expert member in the ISO TC276 Bioprocessing committee. Dr. Karnieli is the founder of Karnieli Ltd and ADVA Biotechnology.